

**In the Claims:**

1. (Original) A bivalent or multivalent antibody characterized by the following features:
  - (a) it is capable of suppressing an immune reaction;
  - (b) it is devoid of constant antibody regions; and
  - (c) it binds an epitope on the CD3 complex of the T-cell receptor.
2. (Original) The antibody of claim 1 that is a diabody.
3. (Original) The antibody of claim 1 that comprises two scFv antibodies linked by a peptide linker.
4. (Original) The antibody of claim 1 that is a single chain diabody.
5. (Currently Amended) The antibody according to ~~any one of claims 1 to 4~~ claim 1, wherein ~~the~~ its variable V<sub>H</sub> and V<sub>L</sub> domains are connected via the peptide linker SAKTTP or SAKTTPKLGG.
6. (Currently Amended) The antibody according to ~~any one of claims 1 to 5~~ claim 1, wherein ~~the~~ its variable domains correspond to the variable domains of ~~the~~ an antibody produced by the hybridoma of ATCC deposit number CRL 8001.
7. (Currently Amended) The antibody according to claim 6, wherein a cysteine at position H100A (~~Kabat numbering system~~) has been exchanged for another amino acid.
8. (Original) The antibody according to claim 7, wherein the cysteine has been exchanged for a serine.

9. (Currently Amended) A polynucleotide, which encodes an antibody ~~of any one of claims 1 to 8~~ according to claim 1.

10. (Original) An expression vector comprising the polynucleotide of claim 9.

11. (Original) The expression vector of claim 10, which is pSKK3-scFv\_6-anti-CD3 (DSM 15137).

12. (Original) A host cell containing the expression vector of claim 10 or 11.

13. (Currently Amended) A pharmaceutical composition ~~containing~~ comprising the antibody of ~~any one of claims 1 to 8~~ claim 1, the polynucleotide of claim 9, or the expression vector of claim 10 ~~or 11~~.

14. (Currently Amended) ~~Use of an antibody which is characterized by the following features:~~  
~~(a) it is capable of suppressing an immune reaction;~~  
~~(b) it is devoid of constant antibody regions; and~~  
~~(c) it binds an epitope on the CD3 complex of the T-cell receptor; or the polynucleotide of claim 9 or the expression vector of claim 10 or 11 for the preparation of a pharmaceutical composition~~ A method for immunotherapy comprising the step of administering to a subject the pharmaceutical composition according to claim 13.

15. (Currently Amended) ~~Use according to claim 14, wherein the antibody is~~ A method for immunotherapy comprising the step of administering to a subject a pharmaceutical composition comprising the antibody of any one of claims 1 to 8 claim 1.

16. (Currently Amended) Use The method according to claim 14 ~~or 15~~, wherein said immunotherapy is a therapy against acute transplant rejections.

17. (Currently Amended) ~~Use of~~ A method for gene therapy comprising the step of administering to a subject a pharmaceutical composition comprising the polynucleotide of claim 9 or the expression vector of claim 10 or 11 for the preparation of a pharmaceutical composition for gene therapy.